Skip to content Skip to menu

Central Database Working Group

Progress Report

A Centralised Reporting System for Medicines Australia Member Companies’ Payments and Transfers of Value to Health Care Professionals

Background

On 24 April 2015 the ACCC issued its final determination granting conditional authorisation of Edition 18 of the Medicines Australia Code of Conduct for a period of five years. The authorisation became effective on 16 May 2015.

A condition of the authorisation is that Medicines Australia must use reasonable endeavours to develop and implement a Central Reporting System (CRS) which will allow the public to access information on payments and transfers of value from all companies to healthcare professionals in a single location, via the internet. This condition also requires Medicines Australia to provide regular six-monthly reports identifying the steps taken each reporting period to develop and/or implement a CRS.

Establishing a Centralised Reporting System 

Since the seventh progress report published in November 2018, we have undertaken the following work.

CRS Development 

Pacific Commerce Pty Ltd, which was contracted in May 2018, has completed the technical construction of the CRS in accordance with specified requirements.  During May-June 2019 Pacific Commerce will engage with Medicines Australia’s member companies to test the system in readiness to include data from the reporting round of 1 November 2018 – 30 April 2019, which will be published in August 2019.

Medicines Australia has updated the collection notices and verification statements used by member companies when engaging with healthcare professionals, to include reference to the CRS rather than publication on individual member company websites.  As previously reported, there may be a small number of healthcare professionals who were contracted prior to revising the collection notice, whose engagement with companies continued during November 2018 – April 2019. These data will not be included in the CRS, but will be included in reports published on individual member company websites.  Over time, Medicines Australia expects the CRS to represent a complete set of reporting data.

Medicines Australia and our member companies will ensure healthcare professionals’ personal information is managed consistent with Australia’s Privacy law.

Sixth Transparency Reports

Medicines Australia continues to assist and advise member companies in preparing their information about reportable payments and transfers of value to individual healthcare professionals. The sixth reports, relating to activities occurring between 1 May and 31 October 2018, were published by member companies on 28 February 2019. Thirty-three member companies published reports on their company websites. These reports are hyperlinked from the Medicines Australia website.

This was the fourth, full six-month reporting period where healthcare professionals reasonably expected their data to be published.  In this reporting period there was one activity reported that had been conducted under the previous informed consent process (prior to 1 October 2016).  That activity, for which the healthcare professional consented to reporting, was included in the published data.   Therefore, no activities were reported in an aggregated form.  This is consistent with the expectation that aggregated data will be phased out over future reporting periods.

Next steps

The work of Medicines Australia and its members in the six months to May 2019 demonstrates significant progress in the development of the CRS whilst delivering transparent reporting of payments and transfers of value to healthcare professionals for activities occurring between May and October 2018.

Medicines Australia will continue work with our member companies and Pacific Commerce Limited to test and finalise the CRS in readiness for publication of data in August 2019.

16 May 2019

Downloadable PDF is also available.

Previous Reports

Top